SPHHP Research Activities Newsletter

University at Buffalo

November/December 2017

In the News

Congratulations to the Following Awardees!



Rachel Hageman Blair, Assistant Professor of Biostatistics, is PI on a new award from UB's Genome, Environment and Microbiome Community of Excellence's (GEM) Education and Engagement Innovation Awards for the project entitled *Introducing High Schoolers to Genetics through Dragon Breeding*. The project will introduce students from Sweet Home Senior High School to the basics of modern genetics. Using GENIQUEST game software developed by the Concord Consortium and The Jackson Laboratory, the students will breed dragons for desired genetic traits, such as color, wings and the ability to breathe fire. Dietrich Kuhlmann, Research Professor of Biostatistics, is Co-Investigator.



Heather Ochs-Balcom, Associate Professor of Epidemiology and Environmental Health, is Co-PI on a new award from UB's Genome, Environment and Microbiome Community of Excellence's (GEM) Education and Engagement Innovation Awards for the project entitled *Revealing Breast Cancer Risk in African-American Women*. The funding will provide for UB faculty to hold focus groups to identify questions and concerns African-American women have about genetic predisposition to breast cancer, and their perception of the benefits, risks and experiences with genetic testing. These findings will guide the development and testing of tailored educational messages on breast cancer risks in African-American communities.



Laura Smith, Assistant Professor of Epidemiology and Environmental Health, is PI on two transfer awards. The first, from Cornell University/NIEHS, is entitled *Mycotoxins in Pregnancy and Birth Outcomes in Zimbabwe*. The study will investigate mycotoxin exposure during pregnancy in rural Zimbabwe and the potential relationship with adverse birth outcomes.

The second award is from Cornell University/Bill and Melinda Gates Foundation for the project entitled *Establishing the Link between Mycotoxin Exposure, Gut Dysfunction and Stunting in Zimbabwean Infants.* The project aims to investigate mycotoxin exposure during infancy in rural Zimbabwe and the potential relationship with the environmental enteropathy and stunting.



Jiwei Zhao, Assistant Professor of Biostatistics, is the Statistician on a continuation award from the National Institute on Deafness and Other Communication Disorders/NIH (PI: Richard Salvi, Communication Disorders & Sciences) for the project entitled *Neural Basis of Hyperacusis*. The study seeks to increase our understanding of the neural mechanisms of hyperacusis and tinnitus and test the efficacy of novel pharmacological agents to treat these two debilitating disorders.

Inside this issue:		
In the News	1	
Grant Clinic	2-3	
NIH Funding: Limited Submissions	3-4	
RFA	5-9	
PAS	9	
PAR	9-16	
PA	16-18	
Words to Live By	18	

Grant Clinic

Upcoming Changes to NIH Submission Process for Due Dates on or after January 25, 2018

- 1.) SUBMISSIONS THROUGH WORKSPACE: Grant applications previously have been prepared using the Legacy application package, which the RAS office has downloaded for each submission. Effective January, the legacy package will no longer be available, and all applications will need to be prepared and submitted through grants.gov/ Workspace. The RAS Office has received training from Sponsored Projects and has already prepared some applications through Workspace. There will be minimal changes in the submission process for Pls. All Pls will receive a grants.gov account upon first submission with the new system. This will allow Pls to review the application prior to submission and print a copy of the application for their records.
- 2.) NEW FORMS: NIH and AHRQ will require the use of revised proposal forms, FORMS-E, also effective January 25, 2108. Major changes in the new form include 1) a consolidation of human subjects, inclusion enrollment and clinical trial information previously collected across multiple agency forms and 2) expansion of form fields for clinical trial information to: a) provide the level of information needed for peer review; b) lead applicants through clinical trial information collection requirements; c) present key information to reviewers and agency staff in a consistent format; and d) align with ClinicalTrials.gov (where possible) and position us for future data exchange with ClinicalTrials.gov. The most recent guide notice regarding Forms E provides FAQs, a link to the revised application guide, and a high level summary of the form changes https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-119.html.

NIH has Released Clinical Trial Specific Parent R01 and Parent R21 FOAs

Parent R01 (PA-18-345) and R21 (PA-18-344) FOAs which require a clinical trial have been published for due dates on or after January 25, 2018. If you are planning an application in response, please review the FOAs thoroughly as some NIH Institutes and Centers will join these parent FOAs and others will jointly or alone publish IC-specific clinical trial FOAs. Unless otherwise noted, these Parent Clinical Trial Required FOAs will accept trials of safety and efficacy, as well as mechanistic and other types of trials. Some ICs will accept only mechanistic trials to these Parent Clinical Trial FOAs. NIH defines a clinical trial as "A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes." A mechanistic study "is designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention." Institutes that have published specific guidelines thus far:

<u>National Center for Complementary and Integrative Health (NCCIH)</u> - NCCIH will only accept applications to the parent FOA that propose human mechanistic trials/studies; no applications will be accepted that include any specific aims that propose to assess efficacy or effectiveness of any intervention.

National Heart, Lung, and Blood Institute - NHLBI will only accept mechanistic studies that meet NIH's definition of a clinical trial in response to PA-18-345 and its reissues.

Center for Scientific Review (CSR) Releases a New Tool to Help Applicants Find a Study Section

The new online Assisted Referral Tool (ART) will make a potential match between the science in your application and an appropriate CSR study section(s). After you enter a summary of your application or specific aims, ART will show you both strong and potential matches, and provide you with direct links to descriptions of those study sections and their roster of reviewers. Your query is confidential. No input text from your application or the fingerprint generated during the search will be retained after your query is completed. Requests for study sections or Institute assignment should be submitted on the optional PHS Assignment Request Form.

NIOSH is Closing February and March 2018 Application Receipt Dates for the Following FOAs:

NOT-OH-18-004	PAR-13-245	Mentored Research Scientist Development Award (K01)
NOT-OH-18-005	PAR-12-200	Occupational Safety and Health Research (R03)
NOT-OH-18-006	PAR-13-129	Occupational Safety and Health Research (R01)

NOT-OH-18-007 PAR-12-252 NIOSH Exploratory/Development Grant Program (R21)

NIOSH anticipates publishing new FOAs in Spring 2018.

NOT-OD-18-004

Guidance on Implementation of the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research (sIRB)

This Notice provides additional guidance on NIH's sIRB final policy, the goal of which is to reduce the burden of the IRB process for multi-site research conducting the same protocol. The policy does not apply to foreign sites or career development (K), institutional training (T) and fellowship (F) awards. Effective for due dates on or after January 25, 2018 applicants will be required to use the new PHS Human Subjects and Clinical Trials Information Form in the application package. The adequacy of the sIRB plan will not factor into the review score or overall rating of the Protection of Human Subjects section, unless the FOA/RFP has specific requirements for the sIRB and associated review criteria. For grant applications, a note may be included in the Summary Statement if the sIRB plan appears to be missing or is incomplete, and this will need to be addressed before an award can be made. For additional information, please see the NIH notice.

NOT-OD-18-011

Statement on Article Publication Resulting from NIH Funded Research

The NIH has noted an increase in the numbers of papers reported as products of NIH funding which are published in journals or by publishers that do not follow best practices promoted by professional scholarly publishing organizations. To protect the credibility of published research, authors are encouraged to publish papers arising from NIH-funded research in reputable journals. Existing resources can assist in this process. Guidance for researchers include: Think, Check, Submit and Academics and Scientists: Beware of predatory journal publishers.

NOT-OD-18-103

Project Outcomes Section of all Interim and Final RPPRs will be Publically Available

NIH will make the Project Outcomes Section of all Interim and Final RPPRs submitted on or after October 1, 2017 available to the general public via the NIH Reporter, thus allowing recipients to provide the general public with a concise summary of the cumulative outcomes or findings of the project at the end of each competitive segment.

NOT-CA-18-002

Request for Information (RFI): Information Resources on Lifestyle and Behavioral Factors Contributing to the Effectiveness of Cancer Therapies

The Office of Cancer Complementary and Alternative Medicine (OCCAM) of the NCI is seeking information on:

1) Existing cancer informational resources (e.g. clinical data sets) that include lifestyle and behavioral information (i.e. diet, physical activity, and stress reduction practices) and outcomes of cancer therapy; 2) Ongoing research projects or clinical trials where there is an opportunity to collect information on lifestyle and behavioral information; 3) Information on planed or potential new research projects or clinical trials to study lifestyle and behavioral factors contributing to the effectiveness of cancer therapies; and 4) Strategies to develop and analyze new cancer informational resources which include lifestyle and behavioral information along with outcomes of cancer therapies. Comments on the topic areas of interest should be submitted electronically to the following link: https://docs.google.com/forms/d/e/ by December 15, 2017.

NIH Funding Opportunities: Limited Submissions

UB prior approval is required for the following funding opportunities. If you are interested in applying to any of the limited submissions listed below, please provide the OVPRED with notification through the Limited Submissions at least 60 days prior to the sponsor's submission deadline before proceeding with an application. The limited submission program is managed by Dr. Kenneth Tramposch on behalf of the OVPRED. He may be contacted at kmt1@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

RFA-CA-17-056 (U10) - Network Group Operations Centers

RFA-CA-17-057 (U10) - Network Group Statistics and Data Management Centers

Limited Competition: NCI National Clinical Trials Network

These FOAs support the comprehensive effort by the NCI to provide the infrastructure for the conduct of national clinical trials through the National Clinical Trials Network (NCTN). The NCTN Network Group Operations Centers will provide scientific leadership for developing and implementing multi-disciplinary, multi-institutional trials in a range of cancer types and special populations with specific scientific strategy and goals. The NCTN Network SDMCs will provide statistical expertise for effective scientific design, conduct, and data management of clinical trials led by the associated NCTN Network Group Operations Center. *Only one application per RFA per institution is allowed*.

Application Due Date: January 19, 2018

RFA-CA-18-001 (F99/K00)

The NCI Predoctoral to Postdoctoral Fellow Transition Award

The purpose of this Award is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. *Only one application per institution is allowed.*

Application Due Date: February 21, 2018

PAR-17-159 (R01)

Data Science Research: Personal Health Libraries for Consumers and Patients

The National Library of Medicine seeks applications for novel informatics and data science approaches that can help individuals gather, manage and use data and information about their personal health. A goal of this program is to advance research and application by patients and the research community through broadly sharing the results via publication, and through open source mechanisms for data or resource sharing. *Only one application per institution is allowed*

Application Due Date: March 19, 2018

PAR-17-340 (RM1) (Clinical Trial Not Allowed)

Collaborative Program Grant for Multidisciplinary Teams

This FOA is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields. *Only one application per institution per review cycle is allowed*.

Application Due Dates: May 7, 2018; September 7, 2018; May 7, 2019; September 7, 2019; May 7, 2020; September 7, 2020

PAR-17-068 (T34)

Maximizing Access to Research Careers Undergraduate – Student Training in Academic Research

The Program is designed to provide structured training programs to prepare high-achieving, underrepresented students for doctoral programs in biomedical research fields. Programmatic activities should include authentic research experiences, academic enhancements, skills development, and mentoring. *Only one application per institution is allowed.*

Application Due Date: May 24, 2018

NIH ANNOUNCEMENT FOR ALL CLINICAL RESEARCHERS

There are a large number of NIH funding opportunities this month, because many of them are re-releases of existing FOAs. NIH is updating these funding opportunities to comply with the new application changes, especially in the human subjects section, that are effective January 25, 2018. Many of the FOAs listed below will note whether a clinical trial is or is not allowed. NIH-defined clinical trial applications must be submitted using Funding Opportunity Announcements (FOAs) that are specifically worded for clinical trials. In the past, clinical trial applications could be submitted for FOAs that were not identified as being clinical-trial specific. Beginning on January 25, 2018, submitting to the wrong FOA will lead to rejection of your application.

To help you to determine whether your application meets the NIH definition of a clinical trial, the following questions have been added to the RAS Proposal Questionnaire: 1) Does the study involve human participant research?; 2) Are participants prospectively assigned to an intervention?; 3) Is the study designed to evaluate the effect of the intervention on the participants?; and 4) Is the effect being evaluated either a health-related biomedical or behavioral outcome? An answer of "Yes" to all four questions means that your research is considered a clinical trial.

NIH Funding Opportunities: Requests for Applications (RFA)

January Due Dates

RFA-CA-17-041 (U01)

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes

This FOA is associated with the <u>Beau Biden Cancer MoonshotSM Initiative</u> that is intended to accelerate cancer research. The purpose is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility.

Application Due Date: January 9, 2018

RFA-MH-18-606 (R01); RFA-MH-18-605 (R34)

Mobile and Connected Health Interventions to Improve Care Continuum and Health Outcomes among Youth with HIV

These FOAs seek to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). They support clinical trials that a) incorporate emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) support real-time clinical decision making, and c) facilitate effective long-term management of HIV. Critical to these FOAs, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.

Application Due Date: January 9, 2018

RFA-HL-18-024 (R01)

Cardiovascular and Pulmonary Research on E-Cigarettes

This FOA invites applications addressing the effects of e-cigarettes on the cardiovascular and pulmonary systems, alone or in combination. Research may examine the effects of the whole e-cigarette aerosol or of individual components or constituents. Research may also examine where aerosols, components, or constituents deposit in the airways and resulting heart and/or lung consequences.

Application Due Date: January 16, 2018

RFA-CA-17-042 (UM1)

RFA-CA-17-043 (U24) - Coordinating Center

Research Centers for Improving Management of Symptoms During and Following Cancer Treatment
These FOAs promote research on the implementation and evaluation of integrated symptom monitoring and
management systems for use in cancer care delivery through a Research Consortium. The focus of the Research
Consortium is to use implementation science approaches to accelerate adoption of integrated systems that collect
patient-reported symptom data and use these data to trigger a clinical response consistent with evidence-based
guidelines. The consortium will consist of three Research Centers and Coordinating Center. The Coordinating Center is
expected to: 1) provide oversight and coordination of the Research Centers and the Steering Committee; 2) ensure
standardized, harmonized data collection across the Research Centers; and 3) establish processes for pooled analyses.

Application Due Date: January 17, 2018

RFA-CA-17-033 (P20)

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

This FOA invites applications for development of translational research programs that are focused upon investigating cancer health disparities. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations.

Application Due Date: January 18, 2018

RFA-CA-17-038 (UG3/UH3)

RFA-CA-17-039 (U24) - Coordinating Center

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)

This FOA promotes research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. The The Coordinating Center will provide administrative support to the ACCSIS Program; assist with identification and collection of common data elements; support the evaluation of locally-developed innovative approaches to increase CRC screening, follow-up, and referral-to-care rates; and develop and coordinate data sharing plans.

Application Due Date: January 18, 2018

RFA-AT-18-002 (R21/R33)

Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants

Applications are encouraged for clinical trials or observational studies that examine the impact of interventions such as mindfulness meditation, cognitive behavioral therapy, or multi-disciplinary rehabilitation for primary or secondary prevention for opioid use disorder (OUD) or as an adjunct to medication assisted treatment (MAT) of OUD. Applications that emphasize treatment of the comorbidities of OUD and chronic pain are of particular interest.

Application Due Date: January 18, 2018

RFA-CA-17-061 (UG1)

NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers

This FOA is one of six FOAs that support the comprehensive effort by the NCI to provide the infrastructure for the conduct of national clinical trials through the National Clinical Trials Network (NCTN). Specifically, this FOA solicits applications that propose to maintain or establish Network Group Integrated Translational Science Centers for the NCI National Clinical Trials Network (NCTN). The NCTN Network Group Integrated Translational Science Centers will provide support for leadership and expertise to facilitate incorporating translational science into Network Group clinical trials, including the conduct of pilot projects to collect preliminary data.

Application Due Date: January 19, 2018

RFA-HD-18-101 (R41/R42); RFA-HD-18-102 (R43/R44)

Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy The purpose of this initiative is to invite applications to stimulate new and innovative multipurpose prevention technologies (MPTs) through the development of new combinations of agents and delivery systems to prevent HIV infection and unintended pregnancy among adolescent girls and young women.

Application Due Date: January 22, 2018

RFA-HS-17-012 (K12)

Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI) Learning Health Systems Mentored Career Development Program

AHRQ, in partnership with PCORI, invites applications for institutional career development awards designed to train clinician and research scientists to conduct patient-centered outcomes research within learning health systems focused on generation, adoption, and application of evidence in order to improve the quality and safety of care.

Application Due Date: January 24, 2018

RFA-DE-18-011 (R35) - clinical trial not allowed

NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR)

The objective of this Award is to provide longer-term support to NIDCR-funded investigators, who are in their mid-career stage, and have outstanding records of research productivity, mentorship and professional service to the research community. It is expected that the SOAR Award will propel the investigator along this career trajectory and allow him/her to embark on ambitious longer-term projects of extraordinary potential within the mission of NIDCR. This award supports research projects for up to eight years.

Application Due Date: January 26, 2018

RFA-DE-18-009 (R01); RFA-DE-18-010 (R21) - clinical trial not allowed

Biology of Aging Dental, Oral and Craniofacial Tissues

The purpose of this FOA is to stimulate collaborative research to understand the biological mechanisms of aging in dental, oral, and craniofacial (DOC) tissues, as they relate to parallel processes in other tissues and organs. The overarching long-term goal of this effort is to improve oral health in older adults by addressing knowledge gaps in our understanding of the basic biology of age-associated changes in health and disease states of DOC tissues.

Application Due Date: January 31, 2018

February Due Dates

RFA-DK-17-011 (DP1) - clinical trial not allowed

Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases

This Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases.

Application Due Date: February 2, 2018

RFA-NS-18-005 (U24) - clinical trial not allowed

BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination

This FOA supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community.

Application Due Date: February 9, 2018

RFA-HL-18-026 (K01) - clinical trial not allowed

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA, issued by the NHLBI, is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This program provides research development opportunities for non-tenured science faculty from nationally underrepresented backgrounds in research, with varying levels of research experience.

Application Due Date: February 20, 2018

RFA-AG-18-019 (U01) - clinical trial optional

Enhancing Central Neural Control of Mobility in Aging

This FOA solicits applications to investigate the central neural control of mobility in older adults without overt neurological diseases using innovative and cutting-edge methods that are emerging in neuroscience, geriatrics and mobility-related fields in aging research communities. This announcement also seeks information on the degree of plasticity in the aging brain and how this may be harnessed to maintain or improve mobility.

Application Due Date: February 21, 2018

RFA-Al-17-037 (R01) - clinical trial optional

Immunity in the Elderly

The goal of this FOA is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections and/or vaccinations, including the effects of chronic inflammation on those responses, and applications that will assess changes in immune processes in dental, oral and craniofacial tissues in the elderly.

Application Due Date: February 22, 2018

Multiple Due Dates

RFA-DA-18-018 (R01) - clinical trial not allowed

BRAIN Initiative: Tools to Target, Identify and Characterize Non-Neuonal Cells in the Brain

The purpose of this FOA is to stimulate the development and validation of novel tools and analytical methods to target, identify and characterize non-neuronal cells in the brain. The cutting-edge tools and methods developed under this opportunity should focus specifically on providing improved points of entry into non-neuronal cell-types (glial and vascular) to enable their inventory and characterization within the CNS and help define how these cells interact among each other and with neuronal cells to impact functional circuitries.

Application Due Date: February 1, 2018, October 4, 2018

RFA-OD-18-002 (R01); RFA-OD-18-003 (R21) - clinical trial optional

Tobacco Regulatory Science

The purpose of these FOAs is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration Center for Tobacco Products CTP). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Application Due Dates: February 13, 2018, July 17, 2018, February 13, 2019

RFA-OD-18-001 (R03) - clinical trial optional

Tobacco Regulatory Science Small Grant Program for New Investigators

The purpose of this FOA is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Only New Investigators who fit the criteria are eligible to apply.

Application Due Dates: February 13, 2018, July 17, 2018, February 13, 2019

RFA-MH-17-604 (R61/R33) - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders

RFA-MH-17-606 (R33) - Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders

The purpose of these FOAs is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. These FOAs support the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel.

Application Due Dates: February 14, 2018; June 15, 2018; October 15, 2018

RFA-MH-17-612 (R34)

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions

This FOA encourages pilot research consistent with <u>NIMH's priorities</u> for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions.

Application Due Dates: February 14, 2018, June 15, 2018, October 15, 2018

RFA-MH-18-700 (Collaborative R01) - clinical trial and participation of two or more collaborative sites required RFA-MH-18-701 (R01) — clinical trial required

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions

These FOA support clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. These FOA also support clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services.

Application Due Dates: February 14, 2018, June 15, 2018, October 15, 2018

RFA-MH-18-702 (R61/R33) - clinical trial required

RFA-MH-18-703 (R33) - clinical trial required

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders These FOAs support early stage testing of pharmacologic or device-based interventions using a protocol design wh

These FOAs support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Application Due Dates: February 14, 2018, June 15, 2018, October 15, 2018

RFA-MH-18-704 (R61/R33) - clinical trial required

RFA-MH-18-705 (R33) – clinical trial required

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders

These FOAs support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach.

Application Due Dates: February 14, 2018, June 15, 2018, October 15, 2018

RFA-MH-18-706 (R34) – clinical trial required

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions

This FOA encourages pilot research consistent with <u>NIMH's priorities</u> or: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, and 2) research on the development and preliminary testing of innovative services interventions.

Application Due Dates: February 14, 2018, June 15, 2018, October 15, 2018

RFA-MH-18-707 (R01) - clinical trial required

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders

This FOA supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention.

Application Due Dates: February 14, 2018, June 15, 2018, October 15, 2018

RFA-HL-17-022 (R21)

Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research This FOA will support meritorious exploratory research relevant to the NHLBI mission using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals.

Application Due Dates: February 15, 2018; October 17, 2018; February 15, 2019; October 17, 2019

NIH Funding Opportunities: Program Announcement with Set-Aside Funds (PAS)

PAS-18-063 (R01) - clinical trial optional

HIV/AIDS High Priority Drug Abuse Research

The National Institutes of Health has recently announced the HIV/AIDS research priorities for the next three to five years NOT-OD-15-137. The goal of this FOA is to stimulate high priority research relevant to drug abuse and HIV/AIDS. In FY 18, NIDA intends to fund 8-12 applications and has set aside is \$6M. In FY 19, NIDA intends to fund approximately 4 applications and has set aside \$2M.

Application Due Dates: Standard dates apply **Expiration Date**: September 8, 2018

NIH Funding Opportunities: Program Announcement Reviewed by an Institute (PAR)

Due to the number of funding opportunities and re-releases, the following have been organized based on topic, not due date

AIDS/HIV

PAR-18-411 (R01) – clinical trial not allowed

Getting to Zero: Understanding HIV Viral Suppression and Transmission in the United States

The purpose of this FOA is to support grants to improve measurement and understanding of viral suppression and HIV transmission in the United States (U.S.) using population-level epidemiology and novel tools from Big Data Science approaches and m/eHealth. The outcome of this research will uncover new knowledge from data to build more effective and context-specific HIV control strategies for the U.S. epidemic.

Application Due Date: March 14, 2018; March 14, 2019; March 13, 2020

Aging/Alzheimer's

PAR-18-028 (R01) – clinical trial required

Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline

This FOA encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.

Application Due Date: February 5, 2018

PAR-18-329 (R43/R44); PAR-18-326 (R41/R42) - clinical trial not allowed

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)

The goal of this announcement is to encourage research grant applications to develop wearable, mobile, or other technology to enable direct, objective, and continuous data capture of everyday functions in individuals at risk for and with AD/ADRD. Functional tasks, what some term instrumental activities and activities of daily living (IADLs/ADLs), include such essential activities as using a telephone (or a cellphone), shopping, doing laundry, preparing nutritionally adequate meals, taking prescribed medications, cleaning the house, and managing finances.

Application Due Dates: Standard dates apply

Expiration Date: January 6, 2020

PAR-18-029 (R01) - clinical trial optional

Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias

This FOA invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Application Due Date: Standard dates apply

Expiration Date: January 8, 2020

PAR-18-177 (R21) - clinical trial optional

T1 Translational Research: Novel Interventions for Prevention and Treatment of Age-related Conditions

This FOA encourages exploratory/developmental research projects to accelerate the pace of development of novel therapeutics involving biologics, pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical findings towards the development of new strategies for prevention and treatment of age-related pathologies.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2018

PAR-18-178 (R21) – clinical trial optional

T2 Translational Research: Research Leading to New Health Care Practices, Community Programs and Policies Affecting Older Persons

This FOA encourages research projects on translational research (T2) directed towards development of health care practices, community programs and policies, including monitoring and quality improvement for pharmacological and non-pharmacological approaches for preventing and treating key health issues affecting the elderly. For the purposes of this FOA, T2 translational research on aging is defined as research to gather information needed to develop or evaluate methods of translating results from clinical studies into everyday clinical practice and health decision making.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2018

Cancer/NCI

PAR-18-341 (R50) Laboratory-based Scientist

PAR-18-342 (R50) Core-based Scientist

NCI Research Specialist

The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Application Due Date: January 17, 2018

PAR-18-361 (U54)

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)

The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students and NCI-designated Cancer Centers. The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.

Application Due Date: January 26, 2018

PAR-18-313 (P50) – clinical trial required

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2018, 2019, and 2020

This program supports state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. A SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities.

Application Due Dates: Standard dates apply

Expiration Date: January 8, 2021

PAR-18-290 (P01) – clinical trial optional

National Cancer Institute Program Project Applications

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Application Due Dates: Standard dates apply

Expiration Date: January 20, 2020

PAR-18-336 (K08) – clinical trial required

PAR-18-337 (K08) – no independent clinical trials

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity

This program provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities.

Application Due Dates: Standard dates apply

Expiration Date: January 8, 2021

PAR-18-364 (K01)

PAR-18-365 (K01) – clinical trial required

NCI Mentored Research Scientist Development Award to Promote Diversity

The purpose of these awards are to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.

Application Due Dates: Standard dates apply

Expiration Date: January 8, 2021

PAR-18-018 (R21) – clinical trial optional

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control

This FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens.

Application Due Dates: Standard dates apply

Expiration Date: May 8, 2019

PAR-18-020 (R21) – clinical trial optional

NCI Clinical and Translational Exploratory/Developmental Studies

This FOA supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/ toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/ toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

Application Due Dates: Standard dates apply

Expiration Date: March 23, 2019

Diet/Physical Activity

PAR-18-324 (R01)

Testing Interventions for Health-Enhancing Physical Activity

This FOA funds highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

Application Due Dates: New Applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020;

October 5, 2020

Resubmissions: March 5, 2018; November 5, 2018; July 5, 2019; March 5, 2020;

November 5, 2020

PAR-18-307 (R21/R33)

Developing Interventions for Health-Enhancing Physical Activity

This FOA funds highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies.

Application Due Dates: New Applications: February 16, 2018; October 16, 2018; June 16, 2019; February 16, 20

2020; October 16, 2020

Resubmissions: March 16, 2018; November 16, 2018; July 16, 2019; March 16, 2020;

November 16, 2020

PAR-18-112 (R21) – clinical trial optional

Diet and Physical Activity Assessment Methodology

This FOA will support research pertinent to improving the measurements of diet and physical activity through the development of better instruments, innovative technologies, and/or applications of advanced statistical/analytic techniques. Research proposed in the applications should be aimed at exploring and optimizing innovative combinations of objective and self-report measures of physical activity or dietary intake in both the general population and its diverse subgroups. **Application Due Date:** June 16, 2018 (new); July 16, 2018 (resubmission).

PAR-18-006 (R01); PAR-18-018 (R21) - clinical trial optional

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival

These FOAs encourage transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2018

PAR-18-007 (R01); PAR-18-017 (R21) - clinical trial optional

Dissemination and Implementation Research in Health

These FOAs encourage investigators to submit research grant applications that will identify, develop, test, evaluate and/ or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

Drug/Substance Abuse/Use

PAR-18-062 (R01) – clinical trial optional

Accelerating the Pace of Drug Abuse Research Using Existing Data

Applications are invited that propose the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization.

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PAR-18-195 (U01) – clinical trial optional

Program for Extramural/Intramural Alcohol Research Collaborations

The objective of this FOA is to bring together the research expertise that, as a functioning collaborative unit, will address key alcohol-based research questions that would not otherwise be possible by the same individuals working towards similar goals in isolation. The goal should address questions that advance the alcohol research field with respect to issues surrounding alcohol use disorders including dependence and the effects of alcohol on health.

Application Due Dates: Standard dates apply

Expiration Date: May 8, 2019

PAR-18-196 (R01) – clinical trial optional

Increasing the Use of Medications for the Treatment of Alcohol Use Disorders

The NIAAA seeks applications to conduct hypothesis-driven research to identify effective methods for increasing the utilization of currently-available medications, by addressing their acceptability (to prescribers and patients), perceived effectiveness, affordability, and feasibility of use within existing care delivery systems.

Application Due Dates: Standard dates apply

Expiration Date: May 8, 2020

PAR-18-083 (R25) – clinical trial optional

NIDA Research Education Program for Clinical Researchers and Clinicians

This FOA is intended to support research education activities that enhance the knowledge of substance abuse and addiction research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/service providers, clinical researchers or optimally a combination of the two.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2018

PAR-18-084 (R21/R33) - clinical trial optional

Integrative Research on Polysubstance Abuse and Addiction

The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2019

PAR-18-085 (R33) - clinical trial optional

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes

This FOA supports applications that focus on data replication and the scalability of novel, targeted addiction treatments. Studies that would fall under the R33 would include studies with theory-derived targets and clearly defined hypotheses about how the proposed treatment directed at changing the target relates to clinical outcomes.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2019

PAR-18-086 (R21/R33) - clinical trial optional

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes

This FOA encourages applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits.

Application Due Dates: Standard dates apply

PAR-18-203 (R21/R33) - clinical trial optional

Leveraging Electronic Health Records for Alcohol Services Research

This FOA seeks low-cost, pragmatic research projects that leverage electronic clinical records to conduct studies that address novel health services questions about the treatment of alcohol use disorders (AUD) in routine clinical care settings. Projects should address questions with direct relevance for improving clinical care for patients with AUD, while contributing to an understanding of the current utility and remaining barriers to using electronic health records in the conduct of AUD treatment services research.

Application Due Dates: Standard dates apply

Expiration Date: May 8, 2020

PAR-18-082 (R03) - clinical trial optional

Behavioral Science Track Award for Rapid Transition (B/Start)

This FOA seeks to facilitate the entry of beginning investigators into the field of behavioral science research related to drug abuse. To be appropriate for a B/Start award, research must be primarily focused on behavioral processes and research questions.

Application Due Dates: Standard dates apply

Expiration Date: January 8, 201

Health Disparities

PAR-18-331 (R01) - clinical trial not allowed

Simulation Modeling and Systems Science to Address Health Disparities

This FOA supports investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities. Simulation Modeling and Systems Science (SMSS) provides avenues for modeling relevant multiple processes, testing plausible scenarios, understanding the magnitude of intended and unintended consequences of specific interventions, and having the option to adjust and refine simulated intervention designs prior to actual implementation testing in the real world. SMSS approaches have been used to guide interventions in clinical preventive care, disaster planning, and for analyzing national health reform strategies.

Application Due Dates: January 10 2018; June 6, 2018; January 8, 2019; June 7, 2019

Institute Specific

PAR-18-114 (R61/R33) Phase Innovation Award

PAR-18-115 (R33) Innovation Award – clinical trial required for both FOAs

Mechanistic Studies Optimize Mind and Body Interventions in NCCIH High Priority Research Topics NCCIH is committed to the rigorous investigation of Mind and Body Interventions to determine their safety and usefulness. For the purposes of this FOA, Mind and Body Interventions are non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative movement approaches (e.g., yoga, tai-chi, qigong), or some combination of these approaches.

Application Due Date: New: February 1, 2018; October 1, 2018; May 31, 2019

Resubmission: February 14, 2018; October 17, 2018; June 14, 2019

PAR-18-113 (P01) – clinical trial optional

Center of Excellence for Research on Complementary and Integrative Health

This Center of Excellence for Research on Complementary and Integrative Health (CERCIH) program is designed to support three or more highly meritorious projects that can offer significant scientific advantages and "synergy" that could not be achieved by supporting the same projects as individual research grants. Each CERCIH must be focused on questions of high relevance to the mission of NCCIH.

Application Due Dates: Standard dates apply

Expiration Date: January 8, 2020

PAR-18-405 (P01) – clinical trial optional

NHLBI Program Project Applications

This FOA invites applications that address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also address implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective.

Application Due Dates: Standard dates apply

PAR-18-118 (U01) - clinical trial required

NCCIH Mind and Body Clinical Trial Cooperative Agreement

This FOA invites cooperative agreement applications for investigator-initiated clinical trials of mind and body interventions in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a clinical trial to develop and test adaptive interventions; optimize the intervention by evaluating which element of a complex intervention are critical for changes in outcome; assessing whether the intervention can be delivered with fidelity across sites in preparation for a future multi-site trial; or collect additional preliminary data such as determining the duration or frequency of the intervention to be used in a future multi-site trial.

Application Due Dates: New: February 2, 2018; June 1, 2018; October 3, 2018; February 1, 2019; May 31, 2019;

October 3, 2019; and January 31, 2020

Resubmission, Revision, and Renewal Applications: October 18, 2017, February 20, 2018, June 14, 2018, October 17, 2018, February 15, 2019, June 14, 2019, October 17, 2019, February 15, 2019, June 14, 2019, October 17, 2019, February 15, 2019, June 18, 2019, October 18, 2019, October 19, 2019, February 19, 2019, Febr

ruary 14, 2020

PAR-18-405 (P01) - clinical trial optional

NHLBI Program Project Applications

This FOA invites applications that address scientific areas relevant to the NHLBI mission including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders. Programs may also address implementation science, health disparities, and translation research that addresses the mission of the Institute. Each application submitted in response to this FOA must include at least three related research projects that share a common central theme, focus, and/or overall objective.

Application Due Dates: Standard dates apply

Expiration Date: January 8, 2021

PAR-18-406 (R61/R33) - clinical trial required

Single-Site Investigator-Initiated Clinical Trials This FOA supports applications relevant to the research mission of the NHLBI to develop and implement phase II and beyond investigator-initiated single-site clinical trials. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results.

Application Due Dates: New Applications: February 13, 2018; June 13, 2018; October 11, 2018; February 13,

2019; June 13, 2019

Resubmission Applications: March 13, 2018, July 13, 2018, November 13, 2018,

March 13, 2019, July 11, 2019

PAR-18-012 (P01) - clinical trial optional

NIDDK Program Projects

This FOA invites submission of investigator-initiated program project applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research.

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PAR-18-042 (R01) – clinical trial optional

Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK

This FOA invites research project applications to conduct ancillary studies to major ongoing clinical research studies, including clinical trials and prospective observational studies. Applications submitted to this FOA must propose to collect new information and/or biological samples directly from participants of the ongoing parent study, and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK.

Application Due Date: Standard dates apply

Expiration Date: January 8, 2019

PAR-18-102 (R21) – clinical trial optional

Small Grants for New Investigators to Promote Diversity in Health-Related Research

This FOA provides support for New Investigators from backgrounds nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the NIDDK.

Application Due Dates: Standard dates apply

PAR-18-267 (R34) - clinical trial optional

Pilot Services Research Grants Not Involving Interventions

The purpose of this FOA is to encourage pilot research consistent with <u>NIMH</u> priorities for services research studies that are not immediate precursors to the development and testing of services interventions. These areas include: 1) studies to identify mutable factors that impact access, utilization, quality, financing, outcomes including disparities in outcomes, or scalability of mental health services, which may serve as targets in future intervention development; 2) development and testing of new research tools, measures, or methods; or 3) testing the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care.

Application Due Dates: Standard dates apply

Expiration Date: September 8, 2018

Newborn/Youth

PAR-18-090 (R01) - clinical trial optional

Natural History of Disorders Identifiable by Screening of Newborns

This FOA encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening.

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PAR-18-228 (R34) – clinical trial required

Pilot Studies to Detect and Prevent Suicide Behavior, Ideation and Self-Harm in Youth in Contact with the Juvenile Justice System

This initiative supports research to test the effectiveness of combined strategies to both detect and intervene to reduce the risk of suicide behavior, suicide ideation, and non-suicidal self-harm (NSSI) by youth in contact with the juvenile justice system. This FOA invites intervention strategies that are designed to be delivered in typical service settings using typically available personnel and resources, to enhance the implementation of interventions that prove effective, enhance their future uptake in diverse settings, and thereby reduce risk of suicide and self-harm in this population. Application Due Dates: Standard dates apply

Expiration Date: September 8, 2019

NIH Funding Opportunities: Program Announcements (PA)

PARENT ANNOUNCEMENTS

Parent R01 and R21 - clinical trial required
PA-18-345 (R01) NIH Research Project Grant
PA-18-344 (R21) NIH Exploratory/Developmental
Research Grant Program

Application Due Date: Standard dates apply

Expiration Date: January 8, 2021

AIDS/HIV

PA-18-136 (R01); PA-18-154 (R21) - clinical trial optional

Functional Wellness in HIV: Maximizing the Treatment Cascade

Cascade

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-071 (R34) - clinical trial optional

Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation

implementation

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-072 (R03) - clinical trial optional

AIDS-Science Track Award for Research Transition

Application Due Date: Standard dates apply **Expiration Date**: September 8, 2018

AGING

PA-18-134 (R01); PA-18-153 (R21) - clinical trial optional

Prevention Research in Mid-Life AdultsApplication Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-409 (R01); PA-18-408 (R21)

Research Grants Using the Resources from the Osteoarthritis Initiative

Application Due Date: Standard dates apply

Expiration Date: May 8, 2021

BEHAVIORAL RESEARCH

PA-18-343 (R15) – clinical trial required

Academic Research Enhancement Award

Application Due Date: Standard dates apply

PA-18-323 (R01); PA-18-322 (R21)

Fundamental Science Research on Mind and Body Approaches

Application Due Dates: Standard dates apply

Expiration Date: January 8, 2021

CANCER

PA-18-002 (R01); PA-18-012 (R21) - clinical trial optional **Examination of Survivorship Care Planning Efficacy** and Impact

Application Due Date: Standard dates apply

Expiration Date: January 8, 2019

PA-18-003 (R01); PA-18-013 (R21) - clinical trial optional Improving Outcomes in Cancer Treatment-Related Cardiotoxicity

Application Due Date: Standard dates apply

Expiration Date: January 8, 2019

PA-18-004 (R01); PA-18-014 (R21) - clinical trial optional Oral Anticancer Agents: Utilization, Adherence, and **Health Care Delivery**

Application Due Date: Standard dates apply

Expiration Date: January 8, 2020

PA-18-005 (R01); PA-18-015 (R21) - clinical trial optional Reducing Overscreening for Breast, Cervical, and **Colorectal Cancers among Older Adults** Application Due Date: Standard dates apply Expiration Date: January 8, 2020

DIET/NUTRITION/PHYSICAL ACTIVITY/OBESITY

PA-18-010 (R01) - clinical trial optional

Diet and Physical Activity Assessment Methodology

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PA-18-034 (R01) - clinical trial optional

Nutrigenetics and Nutrigenomics Approaches for Nutrition Research

Application Due Date: Standard dates apply Expiration Date: September 8, 2019

PA-18-032 (R01) - clinical trial optional

Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PA-18-135 (R01) - clinical trial optional

Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-052 (R21) – clinical trial optional

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-099 (R21) – clinical trial optional

Pilot and Feasibility Clinical and Translational **Research Studies in Digestive Diseases and Nutrition**

Application Due Date: Standard dates apply Expiration Date: September 8, 2018

PA-18-104 (R21) – clinical trial optional

Exploratory/Developmental Clinical Research Grants in Obesity

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-001 (R01) – clinical trial optional

Advancing Translational and Clinical Probiotic/ **Prebiotic and Human Microbiome Research** Application Due Date: Standard dates apply

Expiration Date: May 8, 2021

DRUG/SUBSTANCE USE/ABUSE

PA-18-056 (R01); PA-18-075 (R21) - clinical trial optional **Clinical Development of Minimally-Invasive Bioassays** to Support Outpatient Clinical Trials of Therapeutics for **Substance Use Disorders**

Application Due Date: Standard dates apply Expiration Date: September 8, 2018

PA-18-055 (R01); PA-18-073 (R34); PA-18-074 (R03) -

clinical trial optional

Behavioral and Integrative Treatment Development Program

Application Due Date: Standard dates apply

Expiration Date: January 8, 2019

PA-18-057 (R01) - clinical trial optional

The Application of Big Data Analytics to Drug Abuse Research

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PA-18-058 (R01); PA-18-076 (R21) - clinical trial optional

Prescription Drug Abuse

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

PA-18-060 (R01); PA-18-078 (R21) - clinical trial optional

Neuroscience Research on Drug Abuse Application Due Date: Standard dates apply

PA-18-061 (R01); PA-18-079 (R21); PA-18-080 (R03) clinical trial optional

Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults Application Due Date: Standard dates apply

Expiration Date: May 8, 2020

PA-18-038 (R01); PA-18-043 (R21); PA-18-044 (R03) -

clinical trial optional

Safety and Outcome Measures of Pain Medications **Used in Children and Pregnant Women**

Application Due Date: Standard dates apply

Expiration Date: January 8, 2020

PA-18-065 (R03); PA-18-066 (R21) – clinical trial optional International Research Collaboration on Drug Abuse and Addiction Research

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-067 (R34) – clinical trial optional

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-068 (R34) – clinical trial optional

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

PA-18-069 (R03); PA-18-070 (R21) - clinical trial optional Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco **Abuse**

Application Due Date: Standard dates apply

Expiration Date: May 8, 2018

ENVIRONMENT

PA-18-260 (R01) - clinical trial optional

Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants

Application Due Date: Standard dates apply

Expiration Date: May 8, 2019

HEALTH DISPARITIES

PA-18-284 (R01); PA-18-285 (R21) - clinical trial optional Addressing Health Disparities through Effective Interventions Among Immigrant Populations

Application Due Date: Standard dates apply

Expiration Date: January 8, 2020

PA-18-412 (R01) – clinical trial not allowed

Addressing Health Disparities in NIDDK Diseases

Application Due Date: Standard dates apply

Expiration Date: January 8, 2020

INSTITUTE SPECIFIC

PA-18-287 (R01); PA-18-288 (R21) - clinical trial optional

Improving Outcomes for Disorders of Human Communication

Application Due Date: Standard dates apply

Expiration Date: May 8, 2020

PA-18-330 (R01) - clinical trial required

Investigator-Initiated Clinical Trials Targeting Diseases

within the Mission of NIDDK

Application Due Date: Standard dates apply

Expiration Date: January 8, 2021

NEWBORN/YOUTH

PA-18-031 (R01); PA-18-092 (R21) - clinical trial optional Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their **Infants**

Application Due Date: Standard dates apply Expiration Date: September 8, 2019

PA-18-033 (R01); PA-18-045 (R21); PA-18-046 (R03) -

clinical trial optional

Characterization of the Adolescent Reproductive Tran-

Application Due Date: Standard dates apply Expiration Date: September 8, 2019

PA-18-036 (R01); PA-18-097 (R21); PA-18-053 (R03) -

clinical trial optional

Studies at Periviable Gestation

Application Due Date: Standard dates apply Expiration Date: September 8, 2018

"In a moment of decision, the best thing you can do is the right thing; the next best thing is the wrong thing; and the worst thing you can do is nothing"

Theodore Roosevelt (1858-1919)

